Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

Fiona Powrie © Thomas S. G. Farnetti Wellcome

Wellcome is a global charitable foundation that funds thousands of researchers. It works with academia, philanthropy, businesses, governments, civil society and the public around the world to support science's role in solving health challenges.

With a background in immunology and translational research, Fiona has been a member of Wellcome's Board of Governors since January 2018. She will take up her post in January 2022 from Professor Mike Ferguson, who is stepping down from the Board and Wellcome after 10 years.

Following her appointment, Fiona said: "It is an honour and privilege to serve Wellcome as Deputy Chair. It's an organisation that I've always admired from the beginning of my career. I look forward to working with everyone at Wellcome to help deliver our new strategy that harnesses science and research to improve health for all."

Commenting on her appointment, Julia Gillard, Chair of Wellcome, said: "Fiona's new role as Deputy Chair will allow us to benefit even more from her experience in science and research. I look forward to working with her to drive forward Wellcome's mission to solve the urgent health challenges facing everyone."

Professor Andrew Carr, Head of Department at NDORMS, University of Oxford said: "We send our warm congratulations to Fiona on this new appointment. Fiona's pioneering work in immunology has contributed to a better understanding, prevention and treatment of disease which will help advance global scientific discovery research at Wellcome."

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

NDORMS appoints a new Research Professor of Regulatory Innovation to help accelerate the development pipeline of new treatments

Lincoln Tsang has been appointed as the new John Climax Research Professor of Regulatory Innovation – a new role at NDORMS and the University of Oxford that brings global regulatory and legal expertise to our ambitions to transform and improve drug development pathways in order to help deliver safe and effective treatments to patients sooner. He will assume this role effective 2 January 2027.

Look Beyond My Skin: Your Psoriasis Could Help Us Understand Who Develops Psoriatic Arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

New PI Marie Pust aims to bring microbiome research closer to patients

We welcome Marie-Madlen Pust, who has joined the Kennedy Institute as a new Principal Investigator. Marie will establish a research group combining computational biology with targeted experimental microbiology to identify microbial drivers of chronic inflammatory disease that can be monitored (diagnostic potential) or modified (therapeutic potential).

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.